5-hydroxytryptamine receptor 3D (HTR3D)

5-hydroxytryptamine receptor 3D (HTR3D) is a member of the serotonin (5-HT) receptor family, specifically the 5-HT3 class, which are ligand-gated ion channels belonging to the Cys-loop receptor superfamily. The canonical 5-HT3 receptor operates as a pentameric complex composed of various subunits (A-E); HTR3D encodes the D subunit, which can combine with others (notably 5-HT3A and 5-HT3B) to create functionally and pharmacologically distinct receptors. These receptors are expressed predominantly in the central and peripheral nervous system as well as the gastrointestinal tract, where they mediate fast excitatory neurotransmission by forming cation-selective channels activated by serotonin binding. Functionally, 5-HT3 receptors are implicated in control of gut motility, emesis, visceral sensation, and various psychiatric and neurological states. Therapeutically, drugs targeting these receptors (primarily antagonists) are standard treatments for nausea and vomiting associated with chemotherapy and other GI disorders. The safety of such drugs is influenced by subunit composition, as different combinations affect channel properties and, possibly, drug selectivity and side effects. Note: HTR3D by itself does not form functional channels, but rather functions as one subunit within multimeric 5-HT3 receptor complexes. Its role, disease implications, and pharmacology are less well-studied compared to HTR3A and 5-HT3A/B-containing receptors. Existing literature points to molecular diversity contributed by HTR3D and related genes, which may influence ionic selectivity and channel conductances of 5-HT3 receptors. Currently, all canonical clinical drugs target the 5-HT3 receptor complex; subunit-selective drugs are an active area of research, but none approved yet for HTR3D-specific activity.

Other names

5-HT3-D5HT3DSerotonin receptor 3D5-hydroxytryptamine receptor 3D5-hydroxytryptamine receptor 3D, ionotropic5-hydroxytryptamine receptor 3 subunit Dserotonin 5-HT-3D receptorserotonin receptor 3D5-hydroxytryptamine (serotonin) receptor 3 family member D

Antagonists bind to extracellular domain, block serotonin binding, inhibit opening of the cation-selective channel, and thus prevent depolarization and neurotransmitter release. Allosteric modulation: Some compounds may alter channel activity by binding sites different from the main ligand-binding site.